You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Risk of immunotherapy-related narcolepsy in genetically predisposed patients: a case report of narcolepsy after administration of pembrolizumab

Article metrics

Article menu

Download PDFPDF

XML
Case report
Risk of immunotherapy-related narcolepsy in genetically predisposed patients: a case report of narcolepsy after administration of pembrolizumab

 

Online download statistics by month:

Online download statistics by month: October 2020 to March 2026

AbstractFullPdf
Oct 202042042079
Nov 202014314243
Dec 202023023031
Jan 202113913927
Feb 2021737320
Mar 2021919125
Apr 2021737411
May 2021838322
Jun 202113113114
Jul 2021494914
Aug 2021494914
Sep 2021454516
Oct 2021878733
Nov 2021757728
Dec 2021464611
Jan 2022484917
Feb 202243439
Mar 202251529
Apr 2022474916
May 2022525222
Jun 2022697012
Jul 2022555511
Aug 2022545414
Sep 2022707065
Oct 2022434512
Nov 2022585822
Dec 202238389
Jan 202329297
Feb 2023565710
Mar 2023343424
Apr 2023313233
May 202328288
Jun 202342426
Jul 2023383810
Aug 202334349
Sep 202321216
Oct 202315157
Nov 2023202015
Dec 202324249
Jan 202423239
Feb 2024636311
Mar 2024232336
Apr 2024484821
May 2024495218
Jun 2024292911
Jul 202444459
Aug 202424236
Sep 202426268
Oct 2024464617
Nov 202426277
Dec 202429297
Jan 2025474720
Feb 202577777
Mar 2025434315
Apr 2025484814
May 2025424228
Jun 2025363617
Aug 2025300
Dec 2025400
Jan 2026210
Feb 2026310
Mar 2026200
Total347134741011